Psoriasis onset under dupilumab treatment in two patients affected by atopic dermatitis and one patient affected by alopecia areata: Clinical and dermoscopic patterns.

Dear Editor While dupilumab has emerged as an effective treatment for moderate-to-severe atopic dermatitis (AD) since its approval, interleukin (IL)-4 and 13 blockade has also demonstrated efficacy in off-label chronic dermatologic conditions, such as alopecia areata (AA).1,2 Recently, cases of dupilumab-induced phenotype switching from AD to psoriasis have been reported.3,4 Here, we present three cases of new psoriasis onset under dupilumab treatment: two patients affected by AD and one patient affected by AA. As expected, the histopathologic diagnosis confirmed the diagnosis of psoriasis, and a calcipotriene/betamethasone dipropionate foam was administered once daily for 4 weeks on psoriasis lesions with an improvement of her clinical conditions. [Extracted from the article]